ArticleJournal of cellular and molecular medicine2020

CMap analysis identifies Atractyloside as a potential drug candidate for type 2 diabetes based on integration of metabolomics and transcriptomics.

Hailong Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.